Disease Progression in DLBCL: Management Strategies and Quality-of-Life Considerations

Experts discuss how disease progression impacts patients with diffuse large B-cell lymphoma (DLBCL) and strategies for managing progressive disease based on first-line therapy selection, incorporating insights from the POLARIX 5-year subsequent treatment data and highlighting quality-of-life considerations that influence treatment decisions.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Advances in DLBCL Management: Long-Term Treatment Outcomes

EP: 2.Long-Term Outcomes and Treatment Guidelines in DLBCL Management

EP: 3.Evolving Treatment Strategies in DLBCL: Real-World Clinical Experience

EP: 4.DLBCL Subtype Response Patterns: Optimizing Treatment Selection

Now Viewing

EP: 5.Disease Progression in DLBCL: Management Strategies and Quality-of-Life Considerations

EP: 6.Treatment Decision-Making in DLBCL: Balancing Efficacy, Safety, and Patient Factors

EP: 7.Long-Term Data and Future Directions in First-Line DLBCL Treatment

Video content above is prompted by the following:

Please describe how disease progression impacts patients with DLBCL and the approaches to managing progressive disease based on first-line therapy selection.
• How do the POLARIX 5-year subsequent treatment data inform your approach, and what quality-of-life considerations influence your treatment approach?

Recent Videos

Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring

Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing

Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy

Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_

The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns

Insights from COCOON: Prophylactic Dermatologic Management With Amivantamab + Lazertinib in Advanced NSCLC

1L Treatment for Advanced NSCLC

Recap: ELCC 2025 Highlights

Presented at ELCC 2025: Key Takeaways From KRYSTAL-7

ELCC 2025: Insights From the MARIPOSA Study